Generic Sponsors Need To Increase Communications About Drug Master Files, US FDA Says
Executive Summary
Industry complaining about issues in DMF completeness assessments, but few sponsors schedule teleconferences after complete response letters, FDA says.
You may also be interested in...
FDA Revises Guidance on DMFs and Prior Approval Supplements to Reflect GDUFA II
FDA has revised references in guidance to generic drug user fee requirements that changed under GDUFA II on Oct. 1. One guidance document no longer says for generics firms to pay user fees for prior approval supplement reviews. Another gives review goals for drug master file completeness assessments.
FDA Revises Guidance on DMFs and Prior Approval Supplements to Reflect GDUFA II
FDA has revised references in guidance to generic drug user fee requirements that changed under GDUFA II on Oct. 1. One guidance document no longer says for generics firms to pay user fees for prior approval supplement reviews. Another gives review goals for drug master file completeness assessments.
ANDA Sponsors Get Wide-Open Facility Deadline For Priority Review
User fee legislation says facility information to qualify for priority review must arrive two months in advance of ANDA, conflicting with narrow 'window' in FDA's draft guidance.